Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response to the Ebola Virus Vaccine
PACTR202407858293675Phase 4Not yet recruiting
- Sponsor
- Tulane University
- Start
- Jul 2024
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 arms), sponsored by Tulane University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202407858293675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407858293675.